Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:28 AM
Ignite Modification Date:
2025-12-25 @ 4:28 AM
NCT ID:
NCT05638620
Eligibility Criteria:
Inclusion Criteria:
* Prior confirmed COVID-19 diagnosis by standard RT-PCR assay or equivalent testing
* Persistent symptoms that continue four or more weeks after the start of a COVID-19 infection
* Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31). The COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.
* Quantified pain symptoms of pain interference or pain intensity as reported by the patient on the screener Patient-Reported Outcomes Measurement Information System (PROMIS-29)
Exclusion Criteria:
* Under age 18
* Prior SGB
* Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine/Marcaine)
* Pregnancy
* Current anticoagulant use
* History of a bleeding disorder
* History of glaucoma
* Infection or mass at injection site
* For the consistency of this study, patients who deny all autonomic symptoms on the COMPASS-31 or pain symptoms on the PROMIS-29 will also be excluded
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
100 Years
Study:
NCT05638620
Study Brief:
Protocol Section:
NCT05638620